Radboud Repository

Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/69796

Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging

B. HAVEKES [1, 2], E. W. LAI [1], E. P. M. CORSSMIT [2], J. A. ROMIJN [2], H. J. L. M. TIMMERS [3], K. PACAK [1]

[1]Reproductive Biology and Adult Endocrinology Program
Eunice Kennedy Shriver National Institute
of Child Health and Human Development
National Institutes of Health, Bethesda, MD, USA
[2]Department of Endocrinology and Metabolism Leiden
University Medical Center, Leiden, The Netherlands
[3]Department of Endocrinology
University Medical Center Nijmegen
Nijmegen, The Netherlands

Pheochromocytomas are rare tumors arising from chromaffin cells of adrenal medullary or extra-adrenal paraganglionic tissue. These tumors are characterized by synthesis, storage, metabolism and secretion of catecholamines. Similar to the sympathetic nervous system, pheochromocytomas express cellular norepinephrine transporters (NET) through which catecholamines can enter pheochromocytoma cells to be stored in vesicles. Metaiodobenzylguanidine (MIBG) resemblance to norepinephrine and its good affinity and uptake by NET resulted in its use in pheochromocytoma diagnosis from 1981. Both [^{123}I]MIBG and [^{131}I]MIBG (lower sensitivity) scintigraphy are used for localization of these tumors. Recent discoveries of different hereditary syndromes associated with pheochromocytomas led to the identification of several and new distinct genotype-phenotype associations. Importantly, with this distinction of clinical phenotypes, MIBG was found to have a different performance in subsets of pheochromocytoma patients. Reduced sensitivity of MIBG scintigraphy in some familial paraganglioma syndromes, malignant disease and extra-adrenal paragangliomas has been found. Therefore, newer compounds, especially for positron emission tomography (PET), such as [^{11}C]hydroxyephedrine ([^{11}C]HED), [^{18}F]fluoro-2-deoxy-D-glucose ([^{18}F]FDG), [^{18}F]fluoro-dihydroxyphenylalanine ([^{18}F]FDOPA) and [^{18}F]fluorodopamine ([^{18}F]FDA) have emerged and were found to be superior to MIBG in the localization of certain types of pheochromocytoma and paragangliomas. Finally, using [^{131}I]MIBG represents an important treatment option in patients with malignant pheochromocytoma, but the development of newer treatment modalities is expected. In this review, we provide the reader with an overview of the current standing of [^{123}I]- and [^{131}I]MIBG in diagnosis and treatment of pheochromocytoma amongst the newer PET imaging agents.

KEY WORDS: Pheochromocytomas - Paragangliomas - Radionuclide imaging - Tomography, emission computed.

Corresponding author: K. Pacak, M.D., Ph.D., D.Sc., Professor of Medicine, Chief, Section on Medical Neuroendocrinology, Reproductive Biology and Adult Endocrinology Program, NICHD, NIH, Building 10, CRC, 1-East, Room 1-3140, 10 Center Drive, MSC-1109, Bethesda, Maryland 20892-1109, USA. E-mail: karel@mail.nih.gov

In 2004 the World Health Organization classification of endocrine tumors defined a pheochromocytoma as an intra-adrenal paraganglioma, whereas closely related tumors of extra-adrenal sympathetic or parasympathetic paraganglia are classified as extra-adrenal paragangliomas.[1] In general, approximately 80% of the pheochromocytomas arise from the adrenal medulla.[2] Sympathetic paragangliomas are most frequently found in the abdomen (extra-adrenal),

pelvis and less often in the thorax. These sympathetic paragangliomas almost all produce and most of them secrete catecholamines or their metabolites. On the other hand, head and neck paragangliomas, which were formerly referred to as glomus tumors, are derived from parasympathetic tissue and rarely produce significant amounts of catecholamines. The former estimate that, in general, approximately 10% of paragangliomas and pheochromocytomas are malignant is no longer valid. The prevalence of malignant dedifferentiation depends directly on the underlying genetic mutation.

Metaiodobenzylguanidine (MIBG) is a guanethidine analogue resembling norepinephrine and is, therefore, concentrated by sympatho-adrenergic tissues, especially the chromaffin tissue of the adrenal medulla. The uptake of MIBG in the cells is both driven by passive diffusion and by active uptake.[3] MIBG is an aralkylguanidine that can be labeled with iodine isotopes at the benzoic ring. MIBG is taken up by sympatho-medullary tissues *via* norepinephrine transporters (NET) and deposited in storage granules, which is facilitated by vesicular monoamine transporters (VMAT). MIBG does not bind to postsynaptic adrenergic receptors and, therefore, can be given safely in higher doses. Iodine-131-MIBG has a long half life of approximately 8.2 days, whereas [123I]MIBG has a half life of only 13.2 h. In addition, γ camera efficiency of the 159-keV [123I] isotope is approximately 4 times that of its 364-keV [131I] counterpart and because of the absence of β-emission combined with a shorter half-life, radiation dosimetry is more favorable.[4] To prevent thyroid accumulation it is necessary to block the thyroid gland with potassium iodide. After 24 h and again at either 48 or 72 h after injection of the MIBG the patient will be scanned. MIBG is normally accumulated in myocardium (hence its use in cardiac imaging), liver, spleen, lungs, cerebellum, large intestine and urinary bladder.

In recent years, improvements in diagnosis, genetics, localization, and treatment of pheochromocytomas have changed dramatically the approaches to these tumors. The prevalence of underlying genetic mutations in apparently sporadic pheochromocytomas was found to be much higher than was previously estimated.[5] Hereditary pheochromocytomas occur in multiple endocrine neoplasia type 2, von Hippel-Lindau syndrome (VHL), and neurofibromatosis type 1. The familial paraganglioma syndromes associated with mutations in the succinate dehydrogenase genes (SDHB, C

or D) were more recently discovered as hereditary causes for pheochromocytoma.[6, 7] Several distinct genotype-phenotype associations among SDHB and SDHD mutation carriers have since then been identified.[8-10] For example, patients with a mutation in the SDHB gene have a risk for the development of malignant disease up to 70%, whereas SDHD has been associated with malignant disease in an estimated 2.5-5% of cases.[11, 12] Importantly, the identification of these distinct paraganglioma syndromes prompted a reevaluation of the value of both biochemical tests and radiological imaging in these syndromes separately.

MIBG has been used in pheochromocytoma diagnosis since 1981. However, newer compounds for positron emission tomography (PET) such as [18F]fluorodopamine ([18F]FDA) and [18F]fluoro-dihydroxyphenylalanine ([18F]FDOPA) have been developed in recent years for the diagnosis of pheochromocytomas. This article addresses and reviews three important aspects of MIBG: a) its use as an imaging compound; b) its performance in pheochromocytomas and paragangliomas in comparison to PET compounds; c) its use as a carrier compound for [131I] to treat malignant pheochromocytoma and paraganglioma.

Metaiodobenzylguanidine as an imaging compound in pheochromocytoma and paraganglioma

The radiopharmaceutical agent [131I]MIBG, which was first developed for adrenal scintigraphy and tested on dogs and rhesus monkeys before its use, was reported in a study of 8 pheochromocytoma patients by Wieland *et al.* and Sisson *et al.*[13-15] MIBG was retained for days in tissues where adrenergic vesicles were numerous such as pheochromocytomas, thus offering a means of localization for these tumors. Iodine-131-MIBG scintigraphy was found to have a sensitivity of 77-90% and a specificity of 95-100%.[16-18] Because [123I]MIBG generates a higher dose of γ-rays with a higher specificity, the imaging quality greatly improved. In 1986, Shulkin *et al.* illustrated the superiority of [123I]MIBG over [131I]MIBG in a patient with a primary extra-adrenal pheochromocytoma.[19] Subsequent studies confirmed that the use of the [123I] isotope resulted in a better performance with a sensitivity of 83-100% and a specificity of 95-100%.[18, 20-24] Additional advantages of the [123I] isotope are the possibility to use single photon emission computed

tomography (SPECT) imaging and the fact that a lower half life facilitates the use of higher dosages.

Importantly, the normal adrenal medullary may show physiological uptake of both [131I]- and [123I]MIBG.[25, 26] In [131I]MIBG imaging normal adrenals are visualized in up to 28% of cases (24 and 48 h).[27, 28] Cases studied using [123I]MIBG have been reported to reveal MIBG uptake to a greater extent in normal adrenal medullary tissue than [131I]MIBG.[4] Diffuse adrenal medullary hyperplasia could be responsible for false positive MIBG uptake.[29] However, exemplifying the importance of underlying genetic mutations, this condition appears to be associated with the MEN type 2 syndromes with a well-established risk for pheochromocytoma development. The difficulty is to decide whether or not uptake of [123I]MIBG reflects physiological uptake, adrenal hyperplasia or a pheochromocytoma. In an attempt to improve the accuracy of [123I]MIBG in patients with adrenal or extra-adrenal pheochromocytoma, Cecchin *et al.* assessed the usefulness of a scoring system based on the different uptakes of the radiopharmaceutical between different organs. A scoring system (1: uptake absent or less than liver; 2: uptake equal to the liver; 3: uptake moderately more intense than the liver; 4: uptake intense) was introduced and scintigraphies were classified as positive if there was extra-adrenal focal uptake, adrenal enlargement combined with non-homogeneous uptake or adrenal uptake which was higher than the uptake in the liver (scores 3 and 4).[22] The results were correlated with postoperative histological outcomes and a sensitivity of 91.5% and a specificity of 100% were reported in the localization of adrenal and extra-adrenal pheochromocytomas. Positive and negative predictive values were reported to be 100% and 83%, respectively. According to the authors, using the liver uptake as a reference value resulted in a correct discrimination of physiological adrenal uptake in 18 out of 20 cases.

Suboptimal sensitivity of MIBG might be associated with the relatively low affinity of MIBG to the NET, the lack of storage granules or the loss of NET or VMAT by tumor cell dedifferentiation.[30] Furthermore, several types of medication could interfere with MIBG uptake in patients (Table I) resulting in false-negative results.[31] Several studies have reported the diagnostic value of MIBG scans to be dependent on size and location of the tumor. Reduced sensitivity of MIBG scans in familial paraganglioma syndromes, malignant disease and extra-adrenal paragangliomas has been described.[21, 32-]

TABLE I.—*Interfering pharmaceuticals that may affect imaging with MIBG.*

Interfering pharmaceuticals	Necessary length of cessation before MIBG	Mechanism
Labetalol	72 hours	Inhibition uptake
Reserpine	21 days	Storage depletion
Calcium channel blockers	72 hours	Inhibition uptake
Tricyclic antidepressants	21 days	Storage depletion
Phenylephrine	48 hours	Storage depletion
Pseudoephedrine	48 hours	Storage depletion
Phenylpropanolamine	48 hours	Storage depletion
Ephedrine	48 hours	Storage depletion
Atypical antidepressants Others (e.g. SSRIs)	21 days	Inhibition uptake

MIBG: metaiodobenzylguanidine; SSRI: selective serotonin reuptake inhibitor. [Adapted from: Solanki *et al.*[31]].

[35] Van der Harst *et al.* found MIBG scanning to be less sensitive for familial paraganglioma, malignant disease and extra-adrenal localization.[32] Van der Horst-Schrivers *et al.* reported sensitivity to be 98% for extra-adrenal tumors and 79% in malignant cases.[33] The results in a recent study by Bhatia *et al.*[34] revealed tumor detection in only 58% of the extra-adrenal tumors, whereas 85% of the adrenal pheochromocytomas could be detected. Tumor size correlated with the uptake for adrenal but not for extra-adrenal tumors, which could be a reflection of uptake in small adrenal tumors being obscured by the influence of physiologic adrenal accumulation. Therefore, in general, diagnostic accuracy of MIBG was lower in extra-adrenal and malignant paragangliomas.

With growing knowledge about the genetic background of various pheochromocytoma and paraganglioma syndromes, the evaluation of MIBG scintigraphies focused more on the familial pheochromocytoma and paraganglioma syndromes. Kaji *et al.* reported that 3 out of 7 patients with an adrenal pheochromocytoma associated with VHL had negative results utilizing [123/131I]MIBG.[36] Their results suggested lower sensitivity of MIBG in VHL and they suspected this to be due to the low expression of NET in VHL-related pheochromocytoma cells. The recent discovery of the SDH genes as a hereditary cause for pheochromocytomas and extra-adrenal paragangliomas supported the idea of the existence of different subgroups in familial pheochromocytoma and further addressed the need for proper imaging to detect tumors located outside the adrenals. Several earlier studies, like the

TABLE II.—*Estimated functional imaging performance in separate genotypes.*

	[123/131I]MIBG	specific PET (^{18}F]FDA, [^{18}F]FDOPA)	non-specific PET ([^{18}F]FDG)	Selected references
VHL	+	++	Insufficient data	Kaji *et al.*[36], Hoegerle *et al.*[39]
MEN	+	+	Insufficient data	Greenblatt *et al.*[40], Pacak *et al.*[41]
SDHB	+	++	++/++++*	Timmers *et al.*[10] Timmers *et al.*[38]
SDHC	Insufficient data	Insufficient data	Insufficient data	—
SDHD	+	Insufficient data	Insufficient data	Van Houtum *et al.*[37]
Non-familial**	+**	++**	++**	Hoegerle *et al.*[39], Shulkin *et al.*[42, 43], Mackenzie *et al.*[35]

*Metastatic SDHB-associated disease; **several studies performed before discovery of succinate dehydrogenase gene mutations, SDH associated disease may present as sporadic. MIBG: metaiodobenzylguanidine; PET: positron emission tomography; FDA: fluorodopamine; FDOPA: fluoro-dihydroxyphenylalanine; FDG: fluoro-2-deoxy-D-glucose; VHL: von Hippel Lindau; MEN: multiple endocrine neoplasia; SDH: succinate dehydrogenase type B, C or D; FDG: fluoro-2-deoxy-D-glucose.

paper from van der Harst *et al.*[32] had not specifically addressed MIBG accuracy in SDHD and SDHB mutation carriers separately. It is possible that a considerable number of patients in their large sporadic group were carriers of mutations in the SDH genes, because SDHB-related PGL often present as apparently sporadic tumors, as was described by Timmers *et al.*[10] Only very few studies have investigated the specific value of MIBG scans in SDHD mutation carriers. Based on a study by Van Houtum *et al.*[37] and unpublished data from the Netherlands, we estimate the sensitivity in SDHD patients to be around 80% for detecting pheochromocytomas and extra-adrenal (abdominal and thoracic) paragangliomas combined with an increase in sensitivity to 92% for pheochromocytomas alone. SDHB mutation carriers often display a much more aggressive course of the disease and are prone to developing extra-adrenal malignant disease. Timmers *et al.* reported a sensitivity of only 65% for [123I]MIBG in the evaluation of metastases-positive lesions in SDHB-associated pheochromocytoma and paraganglioma.[38] In conclusion, the different genotype-phenotype associations are most likely also reflected by differences in the performance of imaging with [123/131I]MIBG (Table II).

Some reports have questioned routine use of MIBG imaging in the diagnostic work-up for pheochromocytoma, suggesting that it does not alter the treatment plan in patients with suspected pheochromocytoma in the absence of hereditary disease or a history of pheochromocytoma.[40] In a retrospective study, Miskulin *et al.* concluded that in non-familial cases with a clear biochemical diagnosis and a unilateral adrenal mass on computed tomography (CT) or magnetic resonance imaging (MRI), no additional MIBG imaging is necessary.[44] Although this is a valid recommendation, it needs to be stressed that this is true mainly with regard to epinephrine secreting tumors which are located in the adrenals, whereas the norepinephrine secreting tumors, which are frequently found in familial paraganglioma syndromes, often present recurrent, extra-adrenal, and bilateral disease. Furthermore, especially in older patients, benign adrenal adenomas are often found and can be wrongly considered to be a pheochromocytoma. Another concern with MIBG scintigraphy is that, since MIBG is relatively non-polar, the nonspecific binding is fairly high directly after injection and optimal imaging results are not achieved until 24 h or several days after injection, which is inconvenient for patient care, as is the need to prevent thyroid accumulation with potassium iodide.

Metaiodobenzylguanidine and its performance in pheochromocytomas and paragangliomas in comparison to PET compounds

Because of the above mentioned potential shortfalls of both [123I]- and [131I]MIBG in the imaging of especially extra-adrenal and malignant paragangliomas,

Figure 1.—Chromaffin cell with its specific (left) and less-specific targets (right) for functional imaging. 1: aminoacid uptake; 2: norepinephrine transporter (hNET); 3: somatostatin receptor; 4: GLUT 1 glucose transporter; TH: tyrosine hydroxylase; L-AADC: L-aromatic-aminoacid decarboxylase; DBH: dopamine-β-hydroxylase; PNMT: phenylethanolamine-N-methyltransferase. [Adapted from Ilias *et al.*[45]].

newer means of imaging have been extensively studied. Somatostatin receptors have been demonstrated on paragangliomas (Figure 1) and somatostatin receptor imaging in pheochromocytomas/paragangliomas revealed some favorable results.[46-48] Investigation of [^{111}In]pentetreotide in pheochromocytoma identified most tumors, but appeared to be inferior to the use of MIBG.[49-51] In 2001, van der Harst *et al.* reviewed their experience of preoperative [^{123}I]MIBG and a labeled somatostatin analog in the diagnostic work-up in pheochromocytoma patients and concluded that somatostatin receptor imaging might be considered as a supplement for MIBG in suspected metastatic disease.[32] However, both the expression of NET and the somatostatin receptor may be lost in a dedifferentiated tumor, resulting in false negative imaging in metastatic disease.[32, 51]

PET was developed in the late seventies and has become a more common imaging modality in the imaging of pheochromocytoma in recent years.[52, 53] Compounds used in PET imaging generate positrons that can be detected with high resolution images and their relatively short half-lives compared with other radiopharmaceuticals increases the maximal dose that can be administered safely. PET scanning offers better resolution than SPECT, because signal to noise ratios are increased due to the relatively intense radioactivity and coincidence detection. Furthermore, recent developments enabled to combine conventional imaging methods like CT with PET further improving its diagnostic use.[54] Studies focused on discovery of carriers that could be labeled with positron emitting compounds and still maintain the specificity of MIBG with its selective uptake *via* the NET. Carbon-11-hydroxyephedrine ([^{11}C]HED) is another analogue of norepinephrine and was the first positron-emitting probe of the sympathoadrenal system that was used in humans.[55, 56] In 1992, Shulkin *et al.* reported promis-

ing results of [11C]HED in the localization of pheochromocytoma.[57] Carbon-11-HED is more polar than MIBG, has even greater similarities with norepinephrine and has a very short half-life of only 20 min. Visualization of the [11C] radiotracer was done by the use of PET techniques. The authors reported [11C]HED to accumulate in 9 out of 10 patients, both in benign and malignant pheochromocytoma, only 5 min after injection. However, the synthesis of the [11C]HED compound was very complex and required onsite production for each separate patient because of the very short half-life of the compound. Furthermore, these agents may be subject to interference with the same agents known to interfere with MIBG, because they both use the catecholamine uptake pathway. In conclusion, although [11C]HED had introduced the new field of PET imaging as a promising approach in pheochromocytoma diagnosis, the need for other positron-emitting compounds with a slightly longer half-life, like [18F] (half-life 110 min), was evident.

Fluorine-18-fluorodopamine

Dopamine is a much better substrate for the NET than norepinephrine itself.[30] Therefore, it was hypothesized that a labeled analog of dopamine could be useful for scintigraphy of pheochromocytoma. Fluorine-18-FDA is a sympatho-neuronal imaging agent that was developed at the National Institutes of Health and is a substrate for the transporters in catecholamine synthesizing cells, both those at the membrane and the intracellular vesicular transporters.[30] Fluorine-18 has the advantage that it can usually be incorporated into a molecule with only small effects on the ability of the carrying compound to bind to receptors, or be taken up by their transporters. The result is that the ratio tissue-blood is more than 1 000 which results in a good visualization of cells.[58] Clinical studies have revealed that [18F]FDA is indeed a good imaging agent for pheochromocytoma.[36, 59-61] In 2003, Ilias *et al.* showed the superiority of [18F]FDA imaging over [131I]MIBG scintigraphy, especially in malignant tumors.[62] For PET scanning, patients were studied fasting and caffeine, tobacco and alcohol were avoided for at least 12 h to prevent interference with the imaging, because caffeine is an adrenergic stimulant and the others may influence gastrointestinal motility. However, [18F]FDA is difficult to produce and has limited availability. Like MIBG uptake, uptake of [18F]FDA in normal adrenal glands may lead to false-positive results, because of physiologic uptake. Recently, Timmers *et al.* have reported the usefulness of standardized uptake values for distinguishing adrenal glands with pheochromocytoma from those without.[63] The diagnosis of pheochromocytoma was estimated to be highly unlikely if the SUV was <7.3, whereas a SUV >10.1 confirmed the presence of a pheochromocytoma.

Importantly, the possibility of genotype-specific properties in performance of [18F]FDA imaging must be reemphasized. Its superiority was proven in the detection of pheochromocytoma in a selected cohort of only VHL mutation carriers,[36] however, specific data on [18F]FDA performance in patient cohorts with other genotypes are scarce and will have to be further investigated.

Fluorine-18-dihydroxyphenylalanine

Newer modes of imaging have been developed based on the capabilities of uptake and subsequent decarboxylation of amino acids (like DOPA) in neuroendocrine tumors. DOPA can be decarboxylated to dopamine by L-amino acid decarboxylase (L-AADC), which is shown in Figure 1. This L-AADC enzyme is strongly expressed in neuroendocrine cells and it is evident that cells producing catecholamines may have up regulated amino acid transporters because of the increased demand for precursors. Although, for instance, [11C]methionine and [11C]tyrosine are taken up *via* the same transporter system, they do not accumulate as well in neuroendocrine cells as [18F]FDOPA,[64] suggesting it is only possible for those tracers with a high affinity for L-AADC to remain in the cells. It is suggested that the fact that [18F]FDOPA is converted to [18F]FDA which is subsequently stored in intracellular vesicles may well be the explanation for the ability to localize with these compounds. In 2002, Hoegerle *et al.* described [18F]FDOPA PET imaging to outperform [123I]MIBG scintigraphy in the detection of pheochromocytoma.[39] As was described above, positron emitters tend to have higher spatial resolution and the selective uptake results in imaging within minutes-hours instead of the, at least, 24 h needed in both [123I]- and [131I]MIBG imaging. Furthermore, several studies have noted the lack of uptake in normal adrenal glands,[65, 66] whereas [123I]MIBG reveals some degree of accumulation in normal adrenal glands stressing the importance for evaluation of asymmetric uptake.

Therefore, [18F]FDOPA could be a sensitive and specific tool in the diagnostic strategy of pheochromocytoma and paraganglioma.[64] Timmers *et al.* recently reported that carbidopa enhances the sensitivity of [18F]FDOPA for adrenal pheochromocytomas and extra-adrenal abdominal paragangliomas by increasing the tumor-to-background ratio of tracer uptake. However, the sensitivity of [18F]FDOPA for metastatic paragangliomas was limited.[67]

Fluorine-18-fluoro-2-deoxy-D-glucose

Fluorine-18-fluoro-2-deoxy-D-glucose ([18F]FDG) is the most frequently used PET imaging agent worldwide. Fluorine-18-FDG PET imaging uses the principle of imaging glucose uptake *via* GLUT-1 receptors in tumors with excess uptake of glucose (*e.g.* metabolically active tumor cells). Fluorine-18-FDG is taken into the cells and subsequently trapped by hexokinase-phosphorylation, thus making it resistant to further glycolysis.[68] Fluorine-18-FDG uptake is frequently increased in tumors that are metabolically active and have abundant mitochondria.[69] However, because cancer cells often display high rates of aerobic glycolysis instead of the oxidative phosphorylation pathway *via* the tri-carboxylic-acid cycle (TCA), also termed the Warburg effect, [18F]FDG uptake is not directly proportional to mitochondrial activity alone.[70] However, since [18F]FDG tumor imaging depends primarily on the level of glucose uptake by the tumor cells as a reflection of the level of metabolic activity, it offers little diagnostic specificity. Nonetheless, [18F]FDG localization studies may differentiate between benign and (metabolically more active) malignant tumors. Shulkin *et al.* have reported most pheochromocytomas, both benign and metastasized, to show uptake of [18F]FDG.[42, 43] Fluorine-18-FDG uptake appeared to be unrelated to the secretory status of the tumor. Mann *et al.* reported a study in suspected pheochromocytoma patients where both [11C]HED and [18F]FDG were able to localize more lesions in a more timely fashion than [131I]MIBG.[53] In a recent large study, Timmers *et al.* showed that [18F]FDG is a superior means of visualization in patients with SDHB associated malignant pheochromocytomas.[38] Therefore, we believe [18F]FDG imaging in pheochromocytomas could be reserved for those patients with SDHB metastatic disease or those that had been negative on other functional imaging studies.

Metaiodobenzylguanidine and its role as carrier for ^{131}I to treat malignant pheochromocytoma and paraganglioma

Patients with metastatic paragangliomas have a 5-year-overall survival of approximately 50%.[71] Treatment options in surgically incurable situations are limited. Several studies have reported partial or complete response to have occurred with cyclophosphamide, vincristine and dacarbazine (CVD) chemotherapy.[72] Although chemotherapy may lengthen survival and can be useful for palliative care, the fact that it is associated with significant side effects necessitates an individualized approach. The expression of NET on pheochromocytoma cells does not only provide a method for imaging of these tumors, but could also offer a means for selectively targeting these tumors for treatment.

Iodine-131-MIBG as an experimental treatment for metastasized pheochromocytoma was first reported in 1984.[20, 73] Several studies have since published about the use of [131I]MIBG as a radiotoxic drug to treat pheochromocytomas.[74-78] In 1991, Shapiro *et al.* reported results of a 10 year experience and reported partial tumor response in 8/28 patients with only mild radiotoxicity.[74] A review performed by Loh *et al.* showed tumor response in up to 30% of 116 reported patients.[79] Extended analyses concluded that, in general, a (mostly partial) tumor response was to be expected in 24-45% of the patients, but disease progression after 2 years was common.[80, 81] In line with this finding are the recent results of a retrospective study in 19 patients with a median cumulative dose of 22.2 GBq that revealed tumor response in 47% patient of patients, a biochemical response rate of 67%, whereas no less than 89% of patients mentioned a symptomatic response.[77] Side effects on bone marrow range from mild thrombopenia and leucopenia to overt bone marrow failure, especially in those patients with massive skeletal localizations and higher doses. In addition, although the thyroid had been blocked with potassium iodide, the development of hypothyroidism was possible. Furthermore, higher doses have been reported to result in nausea. However, most studies have been small and had a retrospective design with comparisons made even more difficult because of different doses and treatment intervals.

Usually, patients are treated with multiple medium doses of [131I]MIBG of around 7.4 GBq. Rose *et al.* suggested in 2003 that higher individual doses might

result in increased survival, based upon their study in which 12 patients were treated with a median single treatment dose of 37 GBq leading to 3 patients with a complete and 7 patients with a partial response.[82] Patients had peripheral blood stem cell leukapheresis prior to therapy, unless patients had proven bone marrow metastases. The follow-up study by Fitzgerald *et al.* calculated a 5-year survival of 75% from time of treatment, but stressed the need for newer treatments.[83] Importantly, the level of hematological side effects was much higher; especially grade 3 thrombocytopenia was very frequent (79%). Perhaps repeated intermediate-dosage [131I]MIBG treatment, as was advocated by Lam *et al.* could provide a useful addition in the therapeutic arsenal without the excess of hematological toxicity.[84]

Because malignant pheochromocytomas are rare, no randomized trials have been performed directly comparing the response of CVD chemotherapy with those of [131I]MIBG treatment. In a recent review, Scholz *et al.* concluded that [131I]MIBG therapy and CVD chemotherapy were comparable with regard to both response rate and side effects.[72] As appears to be the case in imaging, treatment results may be expected to vary considerably between patient cohorts with different underlying genetic mutations, which is subject to further prospective and retrospective studies.

Somatostatin receptors have been demonstrated on paragangliomas/pheochromocytomas, and this concept has been used for diagnostic imaging purposes (Figure 1). However, results concerning targeted radionuclide therapy using radiolabeled somatostatin analogues in these tumors are scarcer.[85, 86] Successful use of [177Lu]DOTA0-Tyr3-octreotate in paragangliomas has been reported.[85] Recently, Forrer *et al.* reported that treatment with 90Y- and 117Lu-labeled somatostatin compounds could have long lasting responses with minimal toxicity and could therefore be considered in somatostatin receptor positive surgically incurable paragangliomas.[87] However, most radiolabeled somatostatin analogues target the somatostatin receptor type 2 which may have a low or variable expression, resulting in less efficacy of treatment.[88] Malignant pheochromocytomas may have more expression of type 3 and 5 somatostatin receptors than type 2, so, at least in theory, labeled somatostatin analogues with broader receptor specificity might be more effective in selected cases.[88]

Current treatment options will be further refined in the future. So called 'no-carrier added high specific activity' [131I]MIBG has been reported to improve efficacy of the delivered radiotherapy by increased tumor uptake.[89] Normally, the uptake of [131I]MIBG may be competitively inhibited by the presence of [127I]MIBG, which is formed during the synthesis of [131I]MIBG. Using a 'non-carrier' method of synthesis reduces the amount of 'cold' MIBG with subsequently increased [131I]MIBG uptake and effect of therapy. The development of alternative substrates to MIBG for the NET and storage system will play a role as well. Among these analogues promising results have been suggested for 3-[211At]astatobenzylguanidine ([211At]MABG), which has α-emitting characteristics and a prolonged retention in the targeted tissue.[90, 91]

Local perfusion of affected organs *via* intra-arterial catheters could facilitate the delivery of the radiopharmaceutical compound directly to the tumor in individual patients with metastasized disease located in distinct organs. Brogsitter *et al.* reported patients with carcinoids that had a fourfold increase in local delivery of [131I]MIBG using local perfusion.[92]

Another promising approach is the attempt to increase the expression of key components in the uptake and storage of norepinephrine (and its analogues) to improve the delivery of [131I]MIBG and related radiopharmaceuticals. Recent preliminary developments include increasing tumor accumulation of MIBG by altering NET expression[93, 94] or approaches integrating norepinephrine transporter gene transfer with radionuclide targeting.[95, 96] Some *in vitro* studies suggest MIBG uptake will increase after chemotherapy.[97] Some reports have mentioned doxorubicin and cisplatin increasing the effectiveness of [131I]MIBG as a treatment modality in neuroblastoma.[93, 97, 98]

Conclusions, suggested algorithm and future prospects

In conclusion, the diagnostic and therapeutic strategies in pheochromocytoma have changed dramatically over the last few years. Underlying gene mutations have been identified in a much larger proportion of pheochromocytoma patients than was previously expected. Increased performance of MRI and CT imaging, MIBG, and the emergence of newer means for functional imaging have tremendously increased the diagnostic accuracy in pheochromocytoma diagnosis.

Because of its better accuracy and the fact that they are much more patient friendly, we expect [18F]FDOPA and/or [18F]FDA to (at least partly) replace MIBG in diagnostic imaging for pheochromocytoma and paraganglioma in the future. In metastatic, highly metabolically active SDHB-associated paragangliomas [18F]FDG will certainly be of value, albeit with limited specificity. Future studies will have to take into account the different genotype-phenotype associations with varying imaging performances and provide head-to-head comparisons of imaging methods in these specific subsets of patients. Therapy with [131I]MIBG will remain an essential part of the treatment of malignant pheochromocytomas and paragangliomas, but developments in improving uptake and efficiency can be expected. Currently, clinical trials are being conducted at Duke University with [131I]MIBG preparations synthesized without the unwanted carrier molecules (cold contaminants). Clinical trials comparing high-dose [131I]MIBG *vs* smaller repeated doses *vs* combinations with chemotherapeutic regimens are needed.

References

1. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB *et al.* Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007;3:92-102.
2. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005;366:665-75.
3. Jaques S Jr, Tobes MC, Sisson JC. Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res 1987;47:3920-8.
4. Lynn MD, Shapiro B, Sisson JC, Beierwaltes WH, Meyers LJ, Ackerman R *et al.* Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy. Radiology 1985;155:789-92.
5. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G *et al.* Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459-66.
6. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A *et al.* Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000;287:848-51.
7. Baysal BE. On the association of succinate dehydrogenase mutations with hereditary paraganglioma. Trends Endocrinol Metab 2003;14:453-9.
8. Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K *et al.* Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006;91:827-36.
9. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M *et al.* Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004;292:943-51.
10. Timmers HJ, Kozupa A, Eisenhofer G, Raygada M, Adams KT, Solis D *et al.* Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit b-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 2007;92:779-86.
11. Havekes B, Corssmit EP, Jansen JC, van der Mey AG, Vriends AH, Romijn JA. Malignant paragangliomas associated with mutations in the succinate dehydrogenase D gene. J Clin Endocrinol Metab 2007;92:1245-8.
12. Timmers HJ, Pacak K, Bertherat J, Lenders JW, Duet M, Eisenhofer G *et al.* Mutations associated with succinate dehydrogenase D-related malignant paragangliomas. Clin Endocrinol (Oxf) 2008;68:561-6.
13. Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53.
14. Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM *et al.* Scintigraphic localization of pheochromocytoma. N Engl J Med 1981;305:12-7.
15. Wieland DM, Brown LE, Tobes MC, Rogers WL, Marsh DD, Mangner TJ *et al.* Imaging the primate adrenal medulla with [123I] and [131I] meta-iodobenzylguanidine: concise communication. J Nucl Med 1981;22:358-64.
16. Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 1994;15:356-68.
17. Sisson JC, Shulkin BL. Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 1999;43:217-23.
18. Furuta N, Kiyota H, Yoshigoe F, Hasegawa N, Ohishi Y. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol 1999;6:119-24.
19. Shulkin BL, Shapiro B, Francis IR, Dorr R, Shen SW, Sisson JC. Primary extra-adrenal pheochromocytoma: positive I-123 MIBG imaging with negative I-131 MIBG imaging. Clin Nucl Med 1986;11:851-4.
20. Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 2001;12:469-75.
21. Lumachi F, Tregnaghi A, Zucchetta P, Cristina MM, Cecchin D, Grassetto G *et al.* Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study. Nucl Med Commun 2006;27:583-7.
22. Cecchin D, Lumachi F, Marzola MC, Opocher G, Scaroni C, Zucchetta P *et al.* A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma. Endocr Relat Cancer 2006;13:525-33.
23. Nakatani T, Hayama T, Uchida J, Nakamura K, Takemoto Y, Sugimura K. Diagnostic localization of extra-adrenal pheochromocytoma: comparison of (123)I-MIBG imaging and (131)I-MIBG imaging. Oncol Rep 2002;9:1225-7.
24. Nielsen JT, Nielsen BV, Rehling M. Location of adrenal medullary pheochromocytoma by I-123 metaiodobenzylguanidine SPECT. Clin Nucl Med 1996;21:695-9.
25. Lynn MD, Shapiro B, Sisson JC, Swanson DP, Mangner TJ, Wieland DM *et al.* Portrayal of pheochromocytoma and normal human adrenal medulla by m-[123I]iodobenzylguanidine: concise communication. J Nucl Med 1984;25:436-40.
26. Elgazzar AH, Gelfand MJ, Washburn LC, Clark J, Nagaraj N, Cummings D *et al.* I-123 MIBG scintigraphy in adults. A report of clinical experience. Clin Nucl Med 1995;20:147-52.
27. Lindberg S, Fjalling M, Jacobsson L, Jansson S, Tisell LE. Methodology and dosimetry in adrenal medullary imaging with iodine-131 MIBG. J Nucl Med 1988;29:1638-43.
28. Nakajo M, Shapiro B, Copp J, Kalff V, Gross MD, Sisson JC *et al.* The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983;24:672-82.
29. Yung BC, Loke TK, Tse TW, Tsang MW, Chan JC. Sporadic bilateral adrenal medullary hyperplasia: apparent false positive MIBG scan and expected MRI findings. Eur J Radiol 2000;36:28-31.
30. Eisenhofer G. The role of neuronal and extraneuronal plasma

membrane transporters in the inactivation of peripheral cate-cholamines. Pharmacol Ther 2001;91:35-62.

31. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513-21.

32. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochro-mocytomas. J Clin Endocrinol Metab 2001;86:685-93.

33. Van Der Horst-Schrivers AN, Jager PL, Boezen HM, Schouten JP, Kema IP, Links TP. Iodine-123 metaiodobenzylguanidine scintig-raphy in localising phaeochromocytomas—experience and meta-analysis. Anticancer Res 2006;26:1599-604.

34. Bhatia KS, Ismail MM, Sahdev A, Rockall AG, Hogarth K, Canizales A et al. ^{123}I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) 2008;69:181-8.

35. Mackenzie IS, Gurnell M, Balan KK, Simpson H, Chatterjee K, Brown MJ. The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochro-mocytoma. Eur J Endocrinol 2007;157:533-7.

36. Kaji P, Carrasquillo JA, Linehan WM, Chen CC, Eisenhofer G, Pinto PA et al. The role of 6-[^{18}F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol 2007;156:483-7.

37. van Houtum WH, Corssmit EP, Douwes Dekker PB, Jansen JC, van der Mey AG, Brocker-Vriends AH et al. Increased prevalence of catecholamine excess and phaeochromocytomas in a well-defined Dutch population with SDHD-linked head and neck para-gangliomas. Eur J Endocrinol 2005;152:87-94.

38. Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 2007;25:2262-9.

39. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I et al. Pheochromocytomas: detection with ^{18}F DOPA whole body PET—initial results. Radiology 2002;222:507-12.

40. Greenblatt DY, Shenker Y, Chen H. The utility of metaiodoben-zylguanidine (MIBG) scintigraphy in patients with pheochromo-cytoma. Ann Surg Oncol 2008;15:900-5.

41. Pacak K, Ilias I, Adams KT, Eisenhofer G. Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 2005;257:60-8.

42. Shulkin BL, Koeppe RA, Francis IR, Deeb GM, Lloyd RV, Thompson NW. Pheochromocytomas that do not accumulate metaiodoben-zylguanidine: localization with PET and administration of FDG. Radiology 1993;186:711-5.

43. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 1999;212:35-41.

44. Miskulin J, Shulkin BL, Doherty GM, Sisson JC, Burney RE, Gauger PG. Is preoperative iodine 123 meta-iodobenzylguanidine scintig-raphy routinely necessary before initial adrenalectomy for pheochromocytoma? Surgery 2003;134:918-22.

45. Ilias I, Shulkin B, Pacak K. New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends Endocrinol Metab 2005;16:66-72.

46. Giammarile F, Baudin E, Tenenbaum F, Lumbroso J, Schlumberger M, Rougier P et al. Somatostatin receptor imaging: a preliminary experience in forty-nine patients. Q J Nucl Med 1995;39:121-3.

47. Kwekkeboom DJ, van UH, Pauw BK, Lamberts SW, Kooij PP, Hoogma RP et al. Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 1993;34:873-8.

48. Lamberts SW, Reubi JC, Krenning EP. Validation of somatostatin receptor scintigraphy in the localization of neuroendocrine tumors. Acta Oncol 1993;32:167-70.

49. Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M et al. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors. Q J Nucl Med 1995;39:145-9.

50. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B et al. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochro-mocytoma. J Nucl Med 1995;36:1-6.

51. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL et al. Comparison of somatostatin analog and meta-iodoben-zylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:895-902.

52. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004;25:568-80.

53. Mann GN, Link JM, Pham P, Pickett CA, Byrd DR, Kinahan PE et al. [^{11}C]metahydroxyephedrine and [^{18}F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol 2006;13:187-97.

54. Beyer T, Townsend DW, Blodgett TM. Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med 2002;46:24-34.

55. Schwaiger M, Kalff V, Rosenspire K, Haka MS, Molina E, Hutchins GD et al. Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation 1990;82:457-64.

56. Rosenspire KC, Haka MS, Van Dort ME, Jewett DM, Gildersleeve DL, Schwaiger M et al. Synthesis and preliminary evaluation of car-bon-11-meta-hydroxyephedrine: a false transmitter agent for heart neuronal imaging. J Nucl Med 1990;31:1328-34.

57. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 1992;33:1125-31.

58. Hovevey-Sion D, Eisenhofer G, Kopin IJ, Kirk KL, Chang PC, Szemeredi K et al. Metabolic fate of injected radiolabelled dopamine and 2-fluorodopamine in rats. Neuropharmacology 1990;29:881-7.

59. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treat-ment of pheochromocytoma. Ann Intern Med 2001;134:315-29.

60. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS. 6-[^{18}F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001;38:6-8.

61. Pacak K, Goldstein DS, Doppman JL, Shulkin BL, Udelsman R, Eisenhofer G. A "pheo" lurks: novel approaches for locating occult pheochromocytoma. J Clin Endocrinol Metab 2001;86:3641-6.

62. Ilias I, Yu J, Carrasquillo JA, Chen CC, Eisenhofer G, Whatley M et al. Superiority of 6-[^{18}F]-fluorodopamine positron emission tomog-raphy versus [^{131}I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 2003;88:4083-7.

63. Timmers HJ, Carrasquillo JA, Whatley M, Eisenhofer G, Chen CC, Ling A et al. Usefulness of standardized uptake values for distin-guishing adrenal glands with pheochromocytoma from normal adrenal glands by use of 6-^{18}F-fluorodopamine PET. J Nucl Med 2007;48:1940-4.

64. Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-^{18}F-fluorodihydroxyphenylalanine PET in neu-roendocrine tumors: basic aspects and emerging clinical applica-tions. J Nucl Med 2008;49:573-86.

65. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. ^{18}F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calci-tonin levels. Eur J Nucl Med 2001;28:64-71.

66. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF,

Scheruebl H et al. Whole-body ^{18}F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001;220:373-80.

67. Timmers HJ, Hadi M, Carrasquillo JA, Chen CC, Martiniova L, Whatley M et al. the effects of carbidopa on uptake of 6-^{18}F-fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med 2007;48:1599-606.

68. Kayani I, Groves AM. ^{18}F-fluorodeoxyglucose PET/CT in cancer imaging. Clin Med 2006;6:240-4.

69. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nucl Med Biol 1998;25:317-22.

70. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785-808.

71. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 2004;11:423-36.

72. Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H. Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 2007;92:1217-25.

73. Sisson JC, Shapiro B, Beierwaltes WH, Glowniak JV, Nakajo M, Mangner TJ et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 1984;25:197-206.

74. Shapiro B, Sisson JC, Wieland DM, Mangner TJ, Zempel SM, Mudgett E et al. Radiopharmaceutical therapy of malignant pheochromocytoma with [^{131}I]metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 1991;35:269-76.

75. Shapiro B. Summary, conclusions, and future directions of [^{131}I]metaiodobenzylguanidine therapy in the treatment of neural crest tumors. J Nucl Biol Med 1991;35:357-63.

76. Shapiro B, Sisson JC, Shulkin BL, Gross MD, Zempel S. The current status of radioiodinated metaiodobenzylguanidine therapy of neuro-endocrine tumors. Q J Nucl Med 1995;39:55-7.

77. Gedik GK, Hoefnagel CA, Bais E, Olmos RA. ^{131}I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008;35:725-33.

78. Mundschenk J, Lehnert H. Malignant pheochromocytoma. Exp Clin Endocrinol Diabetes 1998;106:373-6.

79. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (^{131}I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997;20:648-58.

80. Sisson JC. Radiopharmaceutical treatment of pheochromocytomas. Ann N Y Acad Sci 2002;970:54-60.

81. Troncone L, Rufini V. Nuclear medicine therapy of pheochromocytoma and paraganglioma. Q J Nucl Med 1999;43:344-55.

82. Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA et al. High-dose ^{131}I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 2003;98:239-48.

83. Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ et al. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose ^{131}I-metaiodobenzylguanidine (^{131}I-MIBG). Ann N Y Acad Sci 2006;1073:465-90.

84. Lam MG, Lips CJ, Jager PL, Dullaart RP, Lentjes EG, van Rijk PP et al. Repeated [^{131}I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma. J Clin Endocrinol Metab 2005;90:5888-95.

85. van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW et al. Effects of therapy with [^{177}Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 2006;47:1599-606.

86. Duet M, Sauvaget E, Petelle B, Rizzo N, Guichard JP, Wassef M et al. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med 2003;44:1767-74.

87. Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 2008. [Epub ahead of print].

88. Mundschenk J, Unger N, Schulz S, Hollt V, Schulz S, Steinke R et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 2003;88:5150-7.

89. Mairs RJ, Cunningham SH, Russell J, Armour A, Owens J, McKellar K et al. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation. J Nucl Med 1995;36:1088-95.

90. Fullerton NE, Boyd M, Ross SC, Pimlott SL, Babich J, Kirk D et al. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma. Med Chem 2005;1:611-8.

91. Vaidyanathan G, Affleck DJ, Alston KL, Zhao XG, Hens M, Hunter DH et al. A kit method for the high level synthesis of [^{211}At]MABG. Bioorg Med Chem 2007;15:3430-6.

92. Brogsitter C, Pinkert J, Bredow J, Kittner T, Kotzerke J. Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of ^{131}I-MIBG. J Nucl Med 2005;46:2112-6.

93. Armour A, Cunningham SH, Gaze MN, Wheldon TE, Mairs RJ. The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. Br J Cancer 1997;75:470-6.

94. Montaldo PG, Raffaghello L, Guarnaccia F, Pistoia V, Garaventa A, Ponzoni M. Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. Int J Cancer 1996;67:95-100.

95. Boyd M, Cunningham SH, Brown MM, Mairs RJ, Wheldon TE. Noradrenaline transporter gene transfer for radiation cell kill by ^{131}I meta-iodobenzylguanidine. Gene Ther 1999;6:1147-52.

96. Mairs RJ, Cunningham SH, Boyd M, Carlin S. Applications of gene transfer to targeted radiotherapy. Curr Pharm Des 2000;6:1419-32.

97. Meco D, Lasorella A, Riccardi A, Servidei T, Mastrangelo R, Riccardi R. Influence of cisplatin and doxorubicin on ^{125}I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines. Eur J Cancer 1999;35:1227-34.

98. Mastrangelo R, Tornesello A, Riccardi R, Lasorella A, Mastrangelo S, Mancini A et al. A new approach in the treatment of stage IV neuroblastoma using a combination of [^{131}I]meta-iodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer 1995;31A:606-11.